Displaying drugs 11876 - 11900 of 12254 in total
Luveltamab tazevibulin
Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate. It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer).
Investigational
Matched Description: … [A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate …
Carbenoxolone
An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity. [PubChem]
Experimental
Matched Description: … It is used for the treatment of digestive tract ulcers, especially in the stomach. …
RPI-78M
RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).
Investigational
Matched Description: … RPI-78M is being developed for the treatment of multiple sclerosis (MS). …
Bicuculline
Bicuculline is a light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.
Experimental
Matched Description: … Bicuculline is a light-sensitive competitive antagonist of GABAA receptors. …
Matched Categories: … GABA-A Receptor Antagonists …
Matched Categories: … GABA-A Receptor Antagonists …
Onatasertib
Onatasertib (CC-223) has been used in trials studying the treatment and basic science of Multiple Myeloma, Glioblastoma Multiforme, HepatoCellular Carcinoma, Non-small Cell Lung Cancer, and Diffuse Large B-Cell Lymphoma, among others.
Investigational
Matched Description: … Onatasertib (CC-223) has been used in trials studying the treatment and basic science of Multiple Myeloma …
BMS-986104
BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects).
Investigational
Matched Description: … BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind ... Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of …
Iopofosine I-131
Iopofosine I-131 (NM-404 I-131) is under investigation in clinical trial NCT01495663 (Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned).
Investigational
Matched Description: … Iopofosine I-131 (NM-404 I-131) is under investigation in clinical trial NCT01495663 (Dose Escalation Study of …
Ontuxizumab
Ontuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 (TEM-1). It is under investigation in clinical trial NCT01574716 (Sarcoma Study of Morab-004 Utilization: Research and Clinical Evaluation).
Investigational
Matched Description: … Ontuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 ... It is under investigation in clinical trial NCT01574716 (Sarcoma Study of Morab-004 Utilization: Research …
Zofin
Zofin, previously known as Organicell Flow, is a nanoparticle-based therapeutic derived from perinatal sources which is manufactured in a way that retains the naturally occurring microRNAs without the addition of other substances .
Investigational
Matched Description: … of other substances[L31323]. ... Zofin, previously known as Organicell Flow, is a nanoparticle-based therapeutic derived from perinatal ... sources which is manufactured in a way that retains the naturally occurring microRNAs without the addition …
Cry5B
Cry5B is a pore-forming crystal protein produced by and derived from the soil bacterium Bacillus thuringiensis. With demonstrated anthelmintic properties, it has been investigated in the treatment of parasitic intestinal infections.[A259372, A259377]
Investigational
Matched Description: … Cry5B is a pore-forming crystal protein produced by and derived from the soil bacterium _Bacillus thuringiensis ... With demonstrated anthelmintic properties, it has been investigated in the treatment of parasitic intestinal …
Subasumstat
Subasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)).
Investigational
Matched Description: … , Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic ... Subasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability ... Solid Tumors or Relapsed/refractory Hematologic Malignancies and in a Subset With Coronavirus Disease …
RO7300490
RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist. RO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors).
Investigational
Matched Description: … RO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics ... and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants …
OBE101
OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management...
Investigational
Matched Description: … OBE101 is a new weight loss drug developed by Obecure Ltd. ... repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of ... It is a new formulation that is based on the vertigo medication, Betahistine. …
Pipendoxifene
ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer. Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment for metastatic breast cancer.
Investigational
Matched Description: … of breast cancer. ... ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment ... Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an …
TD-2749
TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia and diabetic gastroparesis.
Investigational
Matched Description: … TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug ... design in a drug discovery program dedicated to finding new medicines for GI motility disorders such …
Bizalimogene ralaplasmid
Bizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related Anal or Anal/peri-anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2).
Investigational
Matched Description: … NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of …
2-hydroxy-7-methoxy-5-methyl-naphthalene-1-carboxylic acid meso-2,5-dihydroxy-cyclopent-3-enyl ester
2-hydroxy-7-methoxy-5-methyl-naphthalene-1-carboxylic acid meso-2,5-dihydroxy-cyclopent-3-enyl ester is a solid. This compound belongs to the naphthalenecarboxylic acids and derivatives. These are compounds containing a napthalene moiety with a ring carbon which bears a carboxylic acid group or a derivative. This drug targets the protein neocarzinostatin.
Experimental
Matched Description: … These are compounds containing a napthalene moiety with a ring carbon which bears a carboxylic acid group ... or a derivative. ... hydroxy-7-methoxy-5-methyl-naphthalene-1-carboxylic acid meso-2,5-dihydroxy-cyclopent-3-enyl ester is a …
Displaying drugs 11876 - 11900 of 12254 in total